Stock 4597 SOLASIA PHARMA K.K.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Solasia Pharma K.K.

Equities

4597

JP3436500007

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-07-16 am EDT 		5-day change 1st Jan Change
30 JPY +3.45% Intraday chart for Solasia Pharma K.K. -3.23% -33.33%
May. 15 Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024 CI
Mar. 04 Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024
Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023
Solasia Pharma Narrows Nine-Month Loss as Revenue Gains
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023
Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023
Solasia Pharma K.K. Reports Earnings Results for the First Quarter Ended March 31, 2023
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023
Solasia Partners with WEP Clinical to Supply Darvias [Darvias Injection 135Mg] Under a Named Patient Program
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2023
Solasia Pharma Flags Bigger FY22 Loss Following Unfavorable Results of Cancer Drug Study
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022
An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. from ITOCHU Corporation.
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022
Solasia Announces Summary of SP-04 PledOx Development Status
Solasia gibt Einführung von Darvias® in Japan bekannt
Solasia anuncia el lanzamiento de Darvias® en Japón
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022
Solasia Pharma K.K. Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin)
Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (OM : CAMX).
Solasia Pharma: DARVIAS® als Injektion mit 135 mg (generischer Name: DARINAPARSIN/Entwicklungscode: SP-02) in Japan zugelassen
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4597 Stock
  4. News Solasia Pharma K.K.
  5. Other languages